On September 28, 2026 Pfizer Inc. (NYSE: PFE) reported it will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"At Pfizer Oncology, we’re focused on improving outcomes for people living with cancer. That means continuing to raise the standard of care today while pursuing the breakthroughs that will shape the future of oncology. The data we’re presenting at ESMO (Free ESMO Whitepaper) reflect that focus, strengthening the evidence behind medicines such as PADCEV and TALZENNA, while advancing promising investigational candidates including atirmociclib and tivunatamig. By building on our leadership in breast, genitourinary, and lung cancers, we’re working to bring meaningful progress to patients today and for years to come."
– Jeff Legos, Chief Oncology Officer, Pfizer
Key Highlights of Pfizer’s Presence at ESMO (Free ESMO Whitepaper) 2026
Guiding the Next Wave of Oncology Innovation
Phase 2 randomized results from the FOURLIGHT-1 study of atirmociclib, a highly selective cyclin-dependent kinase (CDK) 4 inhibitor, plus fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC) who had received prior CDK 4/6 inhibitor-based treatment. These results further support atirmociclib as a potential first-in-class cell cycle inhibitor backbone for HR+, HER2- MBC and Pfizer’s development strategy in earlier lines of therapy. A Phase 3 study in frontline MBC is ongoing and an additional Phase 3 study in early breast cancer is planned to evaluate atirmociclib in combination with giredestrant, an investigational oral selective oestrogen receptor degrader under development by Roche. (Presentation #1842O)
Late-breaking overall survival (OS) and progression-free survival (PFS) results from the Phase 3 SigVie-002 study evaluating sigvotatug vedotin (SV), an investigational integrin β6 (IB6)-directed antibody-drug conjugate (ADC), as monotherapy in previously treated non-squamous non-small cell lung cancer (NSCLC). The findings will provide additional insight into previously announced topline results and inform the continued development of SV in earlier treatment settings, including an ongoing Phase 3 trial evaluating SV in combination with pembrolizumab in first-line advanced NSCLC and additional novel combinations under evaluation. (Presentation #LBA68)
Updated Phase 2 data for tivunatamig (PF-08634404, PF’4404), a novel bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in first-line PD-L1-expressing NSCLC. Tivunatamig is being developed as a potential best-in-class backbone therapy designed to combine two validated and complementary pathways in a single agent across tumor types, including ongoing pivotal studies in first-line NSCLC, first-line metastatic colorectal cancer, and advanced/recurrent endometrial cancer. Additional Phase 3 combination studies are planned, including with PADCEV (enfortumab vedotin-ejfv) in metastatic urothelial cancer. (Presentation #2660P)
Expanding Evidence Across the Portfolio
Updated exploratory analyses from the Phase 3 EV-302 trial evaluating outcomes with PADCEV plus pembrolizumab in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC), including among older patients, patients with comorbidities, and subgroups defined by disease-related characteristics. The findings further strengthen confidence in the regimen as a first-line foundation of care in la/mUC across clinically relevant populations. (Presentations #4760P and #4761P)
Results from STARBOARD, a non-registrational Phase 3 trial evaluating an investigational triplet combination regimen of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) with pembrolizumab (KEYTRUDA) in first-line BRAF V600-mutant advanced melanoma. These findings contribute important evidence to an evolving treatment landscape. (Presentation #2071O)
Deepening Understanding of Treatment Outcomes and Patient Experience
Patient-reported outcomes and a safety analysis from the Phase 3 TALAPRO-3 study further supporting TALZENNA (talazoparib) plus XTANDI (enzalutamide) as a potential treatment option for men with homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC; also known as metastatic APMN/S prostate cancer). A supplemental New Drug Application (sNDA) for TALZENNA plus XTANDI in mAPMN/S is currently under Priority Review by the U.S. Food and Drug Administration (FDA). (Presentations #2222RO and #2231P)
An ad-hoc analysis from the Phase 3 EV-303 trial (also known as KEYNOTE-905) and circulating tumor DNA (ctDNA) and health-related quality of life analyses from the Phase 3 EV-304 (KEYNOTE-B15) trial. These analyses provide important biological and patient-centered context to previously reported survival data and further support perioperative PADCEV plus pembrolizumab as a new potential standard of care in muscle-invasive bladder cancer (MIBC). (Presentations #4733O, #4734O and #4738RO)
ESMO Presence Reinforces Pfizer Oncology’s Strategy to Advance Standards of Care and Deliver Next-Generation Breakthroughs
As cancer remains the second-leading cause of death worldwide, Pfizer is focused on generating the evidence needed to bring treatment breakthroughs to as many patients as possible. Our data at ESMO (Free ESMO Whitepaper) reflect that strategy, concentrating innovation in disease areas with the greatest opportunity to impact patients globally. Highlights include emerging data from late-stage investigational programs advancing next-generation treatments, new analyses supporting established medicines as standards of care, and insights that deepen understanding of patient experience to better inform clinical decisions.
Detailed Presentation Information
Information on significant Pfizer and partner-sponsored abstracts, including date and time of presentation, follows in the chart below. A complete list of Pfizer and partner-sponsored abstracts and presentations is available here.
LUNG CANCER
Proffered Paper 1 LBA68
October 25, 2026 10:15–11:45 CET
Phase 3 study of sigvotatug vedotin (SV) vs docetaxel in previously treated non-squamous non-small cell lung cancer (NSCLC) [LBA]
Peters et al
Poster Presentation 2660P
October 26, 2026 12:00–12:45 CET
Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results [3SBio]
Wu et al
BREAST CANCER
Proffered Paper Session 1842O
October 24, 2026 08:30–10:00 CET
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK 4/6 inhibitor (CDK 4/6i) in a randomized phase 2 study (FOURLIGHT-1)
Giordano et al
Proffered Paper Session 1766RO
October 24, 2026 10:15–11:45 CET
Health-related quality of life from HER2CLIMB-05: A Phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
Dieras et al
GENITOURINARY CANCERS: BLADDER AND PROSTATE
Rapid Oral Session 2219RO
October 23, 2026 13:30–15:00 CET
Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC)
Azad et al
Rapid Oral Session 2222RO
October 23, 2026 13:30–15:00 CET
Patient-reported outcomes (PROs) in men with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from the Phase 3 TALAPRO-3 study
Azad et al
Proffered Paper Session 4733O
October 23, 2026 13:30–15:00 CET
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: Ad hoc analysis from KEYNOTE-905 [MSD led]
Ullén et al
Proffered Paper Session 4734O
October 23, 2026 13:30–15:00 CET
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin [MSD led]
Chatzkel et al
Poster Presentation 2296P
October 23, 2026, 15:15-16:00 CET
Safety and efficacy of mevrometostat monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
J. Carles Galceran et al
Poster Presentation 2231P
October 23, 2026 15:15–16:00 CET
Talazoparib (TALA) + enzalutamide (ENZA) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations: Safety analyses from the Phase 3 TALAPRO-3 study
Mateo et al
Poster Presentation 4761P
October 23, 2026 15:15–16:00 CET
Enfortumab vedotin plus pembrolizumab (EV+P) for previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Updated exploratory analysis of EV-302 in older patients (pts) and those with comorbidities
Sridhar et al
Poster Presentation 4760P
October 23, 2026 15:15–16:00 CET
Enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Exploratory analyses based on disease-related characteristics from EV-302
Bedke et al
Proffered Paper Session 4738RO
October 24, 2026 10:15–11:45 CET
Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEYNOTE-B15 study [MSD led]
Gómez De Liaño et al
MELANOMA
Proffered Paper Session 2071O
October 23, 2026 16:15–17:45 CET
STARBOARD Phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (PBO) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma
Schadendorf et al
Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (aPLS) for company-sponsored research being presented at ESMO (Free ESMO Whitepaper), which are written in non-technical language. Those interested in learning more can visit www.Pfizer.com/apls to access the summaries.
Pfizer and Astellas have a clinical collaboration agreement with Merck to evaluate the combination of PADCEV and KEYTRUDA in patients with previously untreated metastatic urothelial cancer and MIBC regardless of cisplatin eligibility. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada). XTANDI is jointly developed and commercialized by Pfizer and Astellas in the United States.
(Press release, Pfizer, SEP 28, 2026, View Source [SID1234671125])